Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective upped by research analysts at Truist Financial from $13.00 to $23.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “hold” rating on the stock. Truist Financial’s target price would suggest a potential upside of 18.50% from the company’s current price.
Several other research analysts have also recently commented on the stock. TD Cowen raised their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Seaport Res Ptn reiterated a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Piper Sandler increased their target price on Hims & Hers Health from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, July 11th. Canaccord Genuity Group initiated coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Seven analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and an average target price of $19.07.
View Our Latest Stock Analysis on Hims & Hers Health
Hims & Hers Health Stock Down 4.7 %
Shares of Hims & Hers Health stock opened at $19.41 on Thursday. The business has a fifty day simple moving average of $20.24 and a 200-day simple moving average of $14.78. The firm has a market cap of $4.17 billion, a price-to-earnings ratio of -1,941.00 and a beta of 1.08. Hims & Hers Health has a fifty-two week low of $5.65 and a fifty-two week high of $25.74.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.05) EPS. Analysts anticipate that Hims & Hers Health will post 0.2 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $12.54, for a total transaction of $2,368,655.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Christiane Pendarvis sold 4,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $12.33, for a total value of $49,320.00. Following the sale, the director now owns 11,210 shares in the company, valued at $138,219.30. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $12.54, for a total transaction of $2,368,655.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 981,653 shares of company stock valued at $18,588,465. 17.71% of the stock is owned by insiders.
Institutional Trading of Hims & Hers Health
Several hedge funds and other institutional investors have recently bought and sold shares of HIMS. Belpointe Asset Management LLC lifted its stake in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after buying an additional 1,205 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Hims & Hers Health by 5.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after acquiring an additional 1,561 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares in the last quarter. Swiss National Bank grew its holdings in shares of Hims & Hers Health by 0.7% during the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after purchasing an additional 2,000 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in shares of Hims & Hers Health by 10.0% during the first quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after purchasing an additional 2,023 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Further Reading
Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
